JP2015533806A - 関節リウマチの治療 - Google Patents

関節リウマチの治療 Download PDF

Info

Publication number
JP2015533806A
JP2015533806A JP2015532412A JP2015532412A JP2015533806A JP 2015533806 A JP2015533806 A JP 2015533806A JP 2015532412 A JP2015532412 A JP 2015532412A JP 2015532412 A JP2015532412 A JP 2015532412A JP 2015533806 A JP2015533806 A JP 2015533806A
Authority
JP
Japan
Prior art keywords
antibody
administered
dose
csf
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015532412A
Other languages
English (en)
Japanese (ja)
Inventor
ヘールトル，シュテファン
ルクレール，ステファヌ
シェブル，アムガッド
シュタイドル，シュテファン
Original Assignee
モルフォシス・アー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォシス・アー・ゲー filed Critical モルフォシス・アー・ゲー
Publication of JP2015533806A publication Critical patent/JP2015533806A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015532412A 2012-09-20 2013-09-19 関節リウマチの治療 Pending JP2015533806A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
EP12185235.4 2012-09-20
US201261703871P 2012-09-21 2012-09-21
US61/703,871 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018061614A Division JP2018138551A (ja) 2012-09-20 2018-03-28 関節リウマチの治療

Publications (1)

Publication Number Publication Date
JP2015533806A true JP2015533806A (ja) 2015-11-26

Family

ID=46963526

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015532412A Pending JP2015533806A (ja) 2012-09-20 2013-09-19 関節リウマチの治療
JP2018061614A Pending JP2018138551A (ja) 2012-09-20 2018-03-28 関節リウマチの治療
JP2022133957A Pending JP2022169709A (ja) 2012-09-20 2022-08-25 関節リウマチの治療
JP2024135431A Withdrawn JP2024156992A (ja) 2012-09-20 2024-08-14 関節リウマチの治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018061614A Pending JP2018138551A (ja) 2012-09-20 2018-03-28 関節リウマチの治療
JP2022133957A Pending JP2022169709A (ja) 2012-09-20 2022-08-25 関節リウマチの治療
JP2024135431A Withdrawn JP2024156992A (ja) 2012-09-20 2024-08-14 関節リウマチの治療

Country Status (22)

Country Link
US (4) US20150246969A1 (enExample)
EP (3) EP3916013A1 (enExample)
JP (4) JP2015533806A (enExample)
KR (4) KR20230041086A (enExample)
CN (2) CN104995210A (enExample)
AU (2) AU2013320261A1 (enExample)
BR (1) BR112015006189B1 (enExample)
CL (2) CL2015000696A1 (enExample)
CR (1) CR20150153A (enExample)
DO (1) DOP2015000070A (enExample)
EA (1) EA031489B1 (enExample)
HK (1) HK1208231A1 (enExample)
IL (1) IL237554B (enExample)
IN (1) IN2015KN00657A (enExample)
MA (1) MA37946B1 (enExample)
MX (2) MX382937B (enExample)
MY (1) MY175388A (enExample)
PE (1) PE20151079A1 (enExample)
PH (1) PH12015500591A1 (enExample)
SG (2) SG11201501595YA (enExample)
UA (1) UA117228C2 (enExample)
WO (1) WO2014044768A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536931A (ja) * 2012-10-31 2015-12-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む液体製剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
RU2714919C2 (ru) * 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545632A (ja) * 2005-05-18 2008-12-18 モルフォシス・アクチェンゲゼルシャフト 抗ｇｍ−ｃｓｆ抗体とその使用
JP2010510323A (ja) * 2006-11-21 2010-04-02 カロバイオス ファーマシューティカルズ インコーポレイティッド Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100408229B1 (ko) 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
CA2618068C (en) 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
CA2682406A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008122415A1 (en) 2007-04-05 2008-10-16 Sandoz Ag Stable aqueous g-csf formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP3381471B1 (en) * 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
ES2432160T3 (es) 2009-12-31 2013-12-02 Arven Ilac Sanayi Ve Ticaret A.S. Procedimiento novedoso para preparar G-CSF (factor estimulante de colonias de granulocitos)
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545632A (ja) * 2005-05-18 2008-12-18 モルフォシス・アクチェンゲゼルシャフト 抗ｇｍ−ｃｓｆ抗体とその使用
JP2010510323A (ja) * 2006-11-21 2010-04-02 カロバイオス ファーマシューティカルズ インコーポレイティッド Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536931A (ja) * 2012-10-31 2015-12-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む液体製剤

Also Published As

Publication number Publication date
US20180230208A1 (en) 2018-08-16
AU2013320261A1 (en) 2015-04-09
UA117228C2 (uk) 2018-07-10
IL237554B (en) 2019-12-31
JP2022169709A (ja) 2022-11-09
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
PH12015500591B1 (en) 2015-05-11
US10913792B2 (en) 2021-02-09
EP3345923A1 (en) 2018-07-11
CN109999195A (zh) 2019-07-12
IL237554A0 (en) 2015-04-30
MX2021006111A (es) 2021-07-07
EA201590359A1 (ru) 2015-08-31
IN2015KN00657A (enExample) 2015-07-17
BR112015006189B1 (pt) 2022-04-05
AU2016250388B2 (en) 2018-07-19
PE20151079A1 (es) 2015-08-07
EP3916013A1 (en) 2021-12-01
AU2016250388A1 (en) 2016-11-17
EA031489B1 (ru) 2019-01-31
EP2897977A1 (en) 2015-07-29
US20150246969A1 (en) 2015-09-03
US20240417455A1 (en) 2024-12-19
SG10201803778PA (en) 2018-06-28
CN104995210A (zh) 2015-10-21
PH12015500591A1 (en) 2015-05-11
MX382937B (es) 2025-03-13
CA2884124A1 (en) 2014-03-27
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
CL2015000696A1 (es) 2015-10-23
KR20150056846A (ko) 2015-05-27
HK1208231A1 (en) 2016-02-26
KR20220028177A (ko) 2022-03-08
US20210130451A1 (en) 2021-05-06
JP2018138551A (ja) 2018-09-06
KR20240091288A (ko) 2024-06-21
MX2015003644A (es) 2015-09-25
MA37946B1 (fr) 2018-09-28
BR112015006189A2 (pt) 2019-11-26
DOP2015000070A (es) 2015-08-16
JP2024156992A (ja) 2024-11-06
MA37946A1 (fr) 2018-01-31
CR20150153A (es) 2015-09-14
CL2018000933A1 (es) 2018-07-20

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
AU2011293554B9 (en) Treatment for neoplastic diseases
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US20200231666A1 (en) Treatment paradigm
JP7132256B2 (ja) 関節リウマチの治療
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
CN113993543B (zh) 使用抗cd38抗体的组合疗法
CA2884124C (en) Treatment for rheumatoid arthritis
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
HK40064997A (en) Treatment for rheumatoid arthritis with anti-gm-csf antibody
NZ744721A (en) Treatment for rheumatoid arthritis
NZ744721B2 (en) Treatment for rheumatoid arthritis
TW202535463A (zh) Ａｎｃａ相關血管炎之治療
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150519

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171128